Covestro Deutschland Ag

Bayer Intellectual Property Gmbh

Bayer Pharma Aktiengesellschaft

Bayer Aktiengesellschaft

Harvard College

The General Hospital Corporation

The Broad Institute, Inc.

Bayer Materialscience Ag

Covestro LLC

Nmi Naturwissenschaftliches Und Medizinisches Institut an Der Universitat Tubingen

Bayer Aktiengellschaft

Bayer Pharma Aktiengellschaft

Bayer Pharma Aktiegellschaft

Covestro Intellectual Property Gmbh & Co. Kg

Thomas Ernst Müller

Christoph Gürtler

Walter Leitner

Muhammad Afzal Subhani

Burkhard Köhler

Jörg Hofmann

Aurel Wolf

Matthias Wohak

Udo Albus

Klemens Lustig

Michael Hahn

Martina Delbeck

Doris Gehring

Henning Vogt

Björn Rosenstein

Christopher Hugh Rosinger

Martin Jeffrey Hills

Ines Heinemann

Isolde Häuser-Hahn

Katja Zimmermann

Knut Eis

Martina Schäfer

Duy Nguyen

Judith Günther

Carl Friedrich Nising

Steven James Ferrara

Sherif El Sheikh

Stefan Nikolaus Gradl

Timo Stellfeld

David B Sykes

Andreas Janzer

Sven Christian

Claudia Merz

Michael Niehues

Claudine Rangheard

Michael Kröber

Lothar Willms

Pieter Ooms

Reinhard Halpaap

Rick L Adkins

Johann Rechner

Jan Dittgen

Jack R Reese

Heinrich Meier

Niels Lindner

Monika H Schmitt

Christoph Thiebes

Jens Frackenpohl

Ilja Peckermann

Friedhelm Risse

Carsten Koopmans

Urs Rauwald

Luisella Toschi

Stefan Lehr

Gerhard Siemeister

Alexander Straub

Hartmut Nefzger

Hans Briem

Alexandros Vakalopoulos

Hans-Georg Lerchen

Carsten Schmeck

Lars Bärfacker

Hanna Tinel

Joachim Kuhnke

Arwed Cleve

Anne Mengel

Anne-Sophie Rebstock

Christoph Methfessel

Thomas Krahn

Ursula Mönning

Wilhelm Bone

Tobias Marquardt

Kai Laemmerhold

Martin Stelzle

Amaury Ernesto Fernandez-Montalvan

Simon Holton

Henrik Teller

Klaus Münter

Jürgen Klar

Matthias Beat Wittwer

Wilfried Nisch

Marion Hitchcock

Bert Klesczewski

Thomas Mondritzki

Alfred Stett

Mark Meininghaus

Jens Langanke

Jan Heijl

Stefan Grasser

Michael Kessler

Alexey Gromov

Jens Schröder

Katrin Nowak-Reppel

Stefanie Braun

Antje Kahnert

Manfred Möwes

Han Jie Zhou

Changjia Zhao

Kery Liu

Melissa Boultadakis Arapinis

The present invention provides triazolone compounds of general formula (I): in which R, R, R, R, and Rare as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and prophylaxis of diseases, in particular hyperproliferative disorders, as a sole agent or in combination with other active ingredients.

2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH

A method for the production of polyoxazolidinone compounds, comprising the step of reacting an isocyanate compound (A) with an epoxide compound (B) in the presence of a catalyst (C), wherein the isocyanate compound (A) comprises a isocyanate compound (A) wherein the a isocyanate compound (A1) comprising at least two isocyanate groups (I&#x2265;2), preferred two isocyanate groups (I=2), wherein the epoxide compound (B) comprises a epoxide compound (B) and an epoxide compound (B), wherein the epoxide compound (B) is different from the epoxide compound (B) wherein the epoxide compound (B) comprising at least two terminal epoxide groups (F1&#x2265;2), preferred two terminal epoxide groups (F=2), linked together by a linking group (L1) and the epoxide compound (B) comprising at least two terminal epoxide groups (F&#x2265;2)), preferred two terminal epoxide groups (F=2), linked together by a linking group (L), wherein the linking group (L) comprises acyclic and covalent bonds to each other free of conjugated multiple bonds within the main chain, wherein the epoxide compound (B) is present in the epoxide compounds Band B, in an amount of &#x2265;0.01 mol-% to &#x3c;10 mol-%, preferred 1-9 mol-% more preferred 3-8 mol-% based on the molar ratio the terminal epoxide groups in the epoxide compound (B) and of the sum of the terminal epoxide groups in the epoxide compound (B) and terminal epoxide groups in the epoxide compound (B).

Process for the synthesis of polyoxazolidinone compounds

Method for the production of polyoxazolidinone compounds, comprising the reaction of at least one biscarbamate compound (A) with at least one bisepoxide compound (B) in the presence of at least one base (D), at least one Lewis acid catalyst (E), and optionally at least one compound (C), wherein the compound (C) comprising a mono-carbamate group, a mono-isocyanate group and/or a mono-epoxide group, and wherein the base (D) having a pKb-value of &#x2264;9. The invention is also related to the resulting polyoxazolidinone compounds.

Method for the production of polyoxazolidinone polymer compounds

The present invention covers substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular and renal diseases, as a sole agent or in combination with other active ingredients.

Substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof

The present application relates to novel imidazopyridinyl- or imidazopyrimidinyl-substituted, bridged 1,4-diazepane derivatives of formula (I), to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases, and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for treatment and/or prevention of respiratory disorders including, sleep-related respiratory disorders such as obstructive sleep apnoeas and central sleep apnoeas and snoring. Formula (I) in which the ring Q represents a bridged 1,4-diazepane cycle. 

Substituted bridged diazepane derivatives and use thereof as TASK-1 and TASK-3 inhibitors

This invention relates to novel macromers containing dithiocarbonate (or xanthate) groups, novel preformed stabilizers comprising macromers, and novel polymer polyols comprising the novel macromers and/or novel preformed stabilizers. This invention also relates to processes for the preparation of these materials. Other aspects of this invention include foams comprising the novel polymer polyols and a process for preparing foam comprising the novel polymer polyols.

Dithiocarbonate containing polyols as polymer polyol stabilizers

The present invention provides triazolone compounds of general formula (I): in which R, R, R, Rand Rare as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.

The present invention relates to novel diazabicyclically substituted imidazo[1,2-a]pyrimidine derivatives, to methods for producing the same, to the use thereof either alone or in combinations for the treatment and/or prevention of diseases, as well as to their use for preparing medicaments for the treatment and/or prevention of diseases, especially for treatment and/or prevention of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnoea and snoring.

Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders

The present invention relates to a method for producing a prepolymer that contains carbon-carbon multiple bonds, a polyol component A) being reacted with component B) that contains isocyanate groups and the polyol component comprising a polyether carbonate polyol that contains carbon-carbon multiple bonds.

Method for producing a multiple bond-containing prepolymer as elastomer precursor

The present invention provides triazolone compounds of general formula (I): in which R, R, R, Rand Rare as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients. 

The present application relates to novel 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives, to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases, and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for treatment and/or prevention of respiratory disorders including, sleep-related respiratory disorders such as obstructive sleep apnoeas and central sleep apnoeas and snoring.

2-phenyl-3-(piperazinomethyl)imidazo[1,2-A]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders

The present application relates to positive allosteric modulators of the muscarinic M2 receptor, especially to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular disorders and/or renal disorders.

Positive allosteric modulators of muscarinic M2 receptor

The present application relates to novel (2-phenylimidazo[1,2-a]pyridin-3-yl)methyl-substituted perhydropyrrolo[3,4-c]pyrrole derivatives, to methods for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of respiratory disorders including sleep-related respiratory disorders such as obstructive sleep apneas and central sleep apneas and snoring.

Substituted perhydropyrrolo[3,4-c]pyrrole derivatives and the use of same

The present invention relates to polyoxazolidinone compounds, a method for the production of polyoxazolidinone compounds, comprising the step of reacting a biscarbamate compound with a bisepoxide compound in the presence of a mono-carbamate, a mono-isocyanate and/or a mono-epoxide compound as chain regulator and a suitable base having a pKvalue of &#x2264;9 as catalyst. The invention further relates to the use of polyoxazolidinone compounds with high thermal stability.

Process for the synthesis of polyoxazolidinone compounds with high stability

Growing community of inventors

Aachen, Germany

Thomas Ernst Müller